Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

6.285 -0.395 (-5.91%)
Streaming Delayed Price Updated: 1:03 PM EDT, Aug 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies (NASDAQ: TSHA) Receives $50 Million Strategic Investment From Astellas Pharma to Develop AAV-Based Gene Therapeutics
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a biotechnology company that is focused on developing gene therapies to treat monogenic 
Via Spotlight Growth
News headline image
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of β-Hexosaminidase A Enzyme Activity in Patients With GM2 Gangliosidosis
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies to Participate in Panel Discussions at the LifeSci Partners 11th Annual Corporate Access Event
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-120 in Giant Axonal Neuropathy
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies Added to the ICE Biotechnology Index
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Disease and Completion of Next-Generation CLN7 Construct Design
From Taysha Gene Therapies, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.